Company intelligence / Profile preview

MElkin Pharmaceuticals

Orleans, Centre Val De Loire, Francemelkin-pharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company is pursuing preclinical development of two innovative drugs: PepFos for cancer and PepElk for depression and drug abuse. Both have been tested in various models with promising results[10].

Therapeutic areas: OncologyPsychiatryNeurology
Modalities: Synthetic cell-penetrating peptides
Industry: Biotech

Drug pipeline

1 asset

PepElk

Unknown

Beyond the preview

Go deeper on MElkin Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MElkin Pharmaceuticals.

Explore the full profile